Ryan McDonald | Authors

February 14, 2021

Better progression-free survival, as well as improved responses, were seen when lenvatinib was combined with either pembrolizumab or everolimus versus standard-of-care sunitinib in the treatment of patients with advanced renal cell carcinoma receiving therapy in the frontline setting.

January 28, 2021

Encouraging survival end points are observed with BMS-986012 plus nivolumab in immune checkpoint inhibitor–naïve SCLC, according to data presented at the 2020 World Conference on Lung Cancer.

January 15, 2021

Statistically significant improvements in median progression-free survival were observed in patients with HER2- amplified disease who were treated with pembrolizumab in combination with trastuzumab and cisplatin plus capecitabine compared with those without HER2-amplified disease.

December 10, 2020

The combination of oral paclitaxel and encequidar has the potential to be an effective treatment for patients with radiation-associated breast angiosarcoma.

December 09, 2020

The study found that 53.2% of patients who reported at least 1 substantial symptom while receiving radiotherapy experienced under-recognition of at least 1 of 4 symptoms by their physician.

December 06, 2020

Following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

September 20, 2020

Patients with triple-negative breast cancer experienced improved pathologic complete responses with the addition of neoadjuvant atezolizumab to chemotherapy.

May 31, 2020

When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.

May 28, 2020

Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing.

May 14, 2020

The use of video conference technology significantly reduced anxiety and stress among individuals who provide care for an individual with cancer and live more than 1 hour away from the patient.